Search
Prednicarbate
go.drugbank.com/drugs/DB01130ApprovedIt has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy. … IL-1a is also found in fibroblasts, where it is responsible for proliferation, collagenase induction and IL-6 synthesis, which are related to skin thickness.
Arformoterol
go.drugbank.com/drugs/DB01274ApprovedIt works by relaxing muscles in the airways to improve breathing. … The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients
Categories: Agents to Treat Airway DiseaseDaclizumab
go.drugbank.com/drugs/DB00111ApprovedInvestigationalWithdrawnRegardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by … and confirmed that this decision was not related to any safety concerns associated with the use of Zenapax (daclizumab) [L1744].
Salsalate
go.drugbank.com/drugs/DB01399ApprovedInvestigationalIn contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo. … Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid.
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticSynonyms: o-Salicylsalicylic acid, O-SalicylcylsalicylsäureTelithromycin
go.drugbank.com/drugs/DB00976ApprovedSimilar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. … It is used to treat mild to moderate respiratory infections.
Aripiprazole lauroxil
go.drugbank.com/drugs/DB14185ApprovedAripiprazole lauroxil was initially approved by the FDA in October 2015 under the market name Aristada for the treatment of schizophrenia. … Schizophrenia is characterized by positive symptoms such as delusions, hallucinations, thought disorders, and catanoia, and negative symptoms that include social withdrawal, anhedonia, and flattening of
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeOcriplasmin
go.drugbank.com/drugs/DB08888ApprovedWithdrawnOcriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. … Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.
Omacetaxine mepesuccinate
go.drugbank.com/drugs/DB04865ApprovedInvestigationalWithdrawnIn November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. … used to treat accelerated or chronic phase CML.
Chlorpheniramine
go.drugbank.com/drugs/DB01114ApprovedInvestigationalA histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less dr...
Mixtures: Up and Up Cold Relief, Up and Up Childrens Multi Symptom Cold Pain Relief PlusCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeConcizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigational[L52043] By inhibiting TFPI, concizumab enhances the production of factor Xa via the extrinsic clotting pathway. … [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors.